Combined criteria for dose optimisation in early phase clinical trials

DOI10.1002/SIM.8292MaRDI QIDQ6625215zbMATH OpenFDO

Authors M. Iftakhar Alam, D. Stephen Coad, Barbara Bogacka

Publication date 28 October 2024

Published in Statistics in Medicine (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1002/SIM.8292

zbMATH Keywords

penalty functionadaptive designcontinuation ratio model\(D\)-optimum designphase I/II trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• scientific article; zbMATH DE number 48904 (Why is no real title available?)
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Adaptive design in regression and control
• Adaptive designs for dose-finding based on efficacy-toxicity response
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response
• Adaptive optimization and \(D\)-optimum experimental design.
• Biometric practicesimple benchmark for complex dose finding studies
• Directed walk designs for dose-response problems with competing failure modes
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Elemental information matrices and optimal experimental design for generalized regression models
• Experimental design in a class of models
• Model-oriented design of experiments
• Optimal Designs for Bivariate Logistic Regression
• Optimal designs and limiting optimal designs for a trinomial response
• Optimum experimental designs, with SAS
• Penalized optimal designs for dose-finding
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials

Cited in

(1)

• A combined criterion for optimizing doses in phase I clinical trials

This page was built for publication: Combined criteria for dose optimisation in early phase clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6625215)